Comments
Commented by Armin Schulz on January 14th, 2022 | 11:06 CET
Lufthansa, wallstreet:online, Block - Shares with catch-up potential
The nervousness was palpable as the US indices fell for five days in a row. Reasons for consolidation are quickly found - the Omicron variant, inflation and the fear of rising interest rates provide uncertainty for the bulls. Especially the big tech companies would suffer from an interest rate hike, and many tech stocks were already punished and investors preferred to invest in value stocks. If the interest rate hike comes, there will likely be further markdowns in the tech sector. Today, we look at three companies that we believe could be on the verge of a turnaround.
Read
Commented by Nico Popp on January 14th, 2022 | 10:13 CET
TeamViewer, Meta Materials, Deutsche Bank: Do your research and beat the market
Sometimes the technology that everyone has known for years becomes a game changer overnight. That is what happened at the beginning of the pandemic with the TeamViewer software. Sometimes things turn out differently, and innovations are so revolutionary that it takes a while for the market to recognize the potential. We examine three stocks for their innovation potential and explain whether or not the market understands the equity stories.
Read
Commented by Mario Hose on January 13th, 2022 | 18:11 CET
New research results for Covid-19: BioNTech, Cardiol, Valneva
In the afternoon of today's trading day, the German indices extended the price losses in part after a brief recovery phase. The DAX is currently trading at 15,963 points, down around 0.41%. The psychological mark of 16,000 points was exceeded at midday in phases by more than 75 points. The MDAX last traded at 34,708 points (-0.62%), TecDAX at 3,577 points (-2.26%) and SDAX at 15,976 points with 0.66% in the red. New research results for the treatment and prevention of Covid-19 provide an exciting perspective for investors.
Read
Commented by Carsten Mainitz on January 13th, 2022 | 14:13 CET
dynaCERT, Plug Power, Nikola - Will hydrogen be the comeback of 2022?
Electromobility is an important building block for reducing CO2 emissions. However, batteries are not efficient enough due to their limited range and long charging times, especially in heavy-duty traffic. The most promising technology is hydrogen. However, after a veritable hype last year, many values experienced an abrupt crash after it became clear that the necessary infrastructure was not yet ready. But in 2022, the course could slowly be set, and hydrogen stocks could make the comeback of the year. We took a closer look at three promising candidates.
Read
Commented by André Will-Laudien on January 13th, 2022 | 13:45 CET
Triumph Gold, Delivery Hero, HelloFresh - Exploding like TeamViewer!
Inflation is galloping, so the central banks will have to react soon. In the matter of COVID-19, an endemic is expected after the overcoming of Omicron. That would likely bring a boom to the economies. The high volatility on the capital markets has now manifested itself, and the basis of the argument changes almost daily. For us, it is a suitable opportunity to take a look at highly volatile investment vehicles. Actually, the sails are set, but inflation can still dash the party - but that would again be a buying argument for the precious metals!
Read
Commented by Stefan Feulner on January 13th, 2022 | 12:45 CET
TeamViewer, Saturn Oil + Gas, BP - Target price USD 100
Oil prices continue to rise. A barrel of Brent currently costs USD 84.32 and is thus on the verge of breaking through a double top formation from the highs of 2018 and 2021. A breakout would generate a fresh buy signal, the target range of which already lies beyond the USD 100 mark. Underpinned by an easing of the Corona situation and an unexpected onset of winter in the US, a new 10-year high at USD 122.88 could even beckon. The primary beneficiaries of this inflationary development are once again the oil producers.
Read
Commented by Mario Hose on January 13th, 2022 | 12:01 CET
Stocks offer trading opportunities: BrainChip, TeamViewer, XPhyto
On Thursday, most German indices started trading with negative signs. The DAX is currently trading at 15,989 points, down around 0.25%. The psychological mark of 16,000 points has not held compared to the previous day. The MDAX last traded at 34,874 points (-0.14%), TecDAX at 3,637 points (-0.62%) and SDAX at 16,062 points with 0.13% in the red. In the single stocks, on the other hand, there are exciting developments for the stock traders.
Read
Commented by Nico Popp on January 13th, 2022 | 11:03 CET
Bayer, First Hydrogen, NEL: This is how innovative investing works!
Innovation pays off - especially on the stock market. That is because innovative products generate price fantasy, which can generate rich returns on the stock market within a very short period of time. In addition to classic trend themes, such as hydrogen, established companies can also score with innovations. We present three stocks and explain whether they offer opportunities or not.
Read
Commented by Nico Popp on January 13th, 2022 | 10:23 CET
JinkoSolar, Barsele Minerals, Barrick Gold: Where challenges are opportunities
The road to success is sometimes rocky and characterized by imponderables. Especially on the stock market, unclear situations can be good opportunities in the long run. Sometimes the market doesn't buy a company's long-term plans, or a fundamental situation overshadows what is actually a good investment story. We present three companies where there is currently a bit of sand in the gears and explain whether opportunities can arise.
Read
Commented by Armin Schulz on January 12th, 2022 | 13:42 CET
Bayer, XPhyto Therapeutics, MorphoSys - Which pharmaceutical companies bring returns?
Most recently, the pharmaceutical industry has been accused of being greedy and getting rich off Corona. While it is true that 2021 has been dominated by vaccine news, the industry can do much more than just produce vaccines against Corona. Handelsblatt ran a headline on January 10, "In the shadow of Corona," citing the growing number of cancers over the past several years. This year, more than 45 new drugs are expected to hit the market to help fight cancer and genetic defects, among other things. Today, we look at three companies that do not make Corona vaccines.
Read